Hyman DM, Willis T, Kummar S, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. J Clin Oncol 35, 2017 (suppl; abstr LBA2501).
Risdiplam bij zuigelingen met SMA type 1: vergelijking met historische controles
aug 2021 | Bewegingsstoornissen, Neuro-musculair